Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

4,207 results
  1. ... BRAF V600K mutation had a response to vemurafenib. AEs required dose modification or interruption in 38% of patients who ... similar outcomes. Median OS has not been reached. AEs leading to dose interruptions occurred in 35% of patients in the ...
  2. ... cathartic, and is used in obstinate visceral obstructions, Ae. Dose, gr. vj to Z se, gr. x to ^ ... gen- tiana, summit, ehamadr., centaur, min. aa p. ae.) Dose, ^ss to ^j. Pulvis Emmenagogus, P. myrrhae compositus — p. ...
  3. ... dose aripiprazole for bipolar disorder. Key Points: Major AEs The effects between different doses of SGAs in terms of major AEs during ... least low SOE for an outcome of general AEs in studies comparing different doses of SGAs. The doses considered are identified for ...
  4. ... Mortality: NR 4) Morbidity: NR 5) Safety: Any AE: Valsartan (any dose): 62.6% Lisinopril (either dose): 58.3% AEs ... rating: Fair Comments: - Numbers screened and eligible NR - AEs not well reported - Details of dose titration and concomitant med use (if any) not ...
  5. ... absinth., tanaceti, fol. scordii, sennae, rhei., aa p. ae); dose, TT(J to 3j. P. hydrago'gus, P. ... spiritus aetheris sulphuric., Oj). Stimulant in nervous affections; dose, S. ae'theris chlora'ti, spiritus aetheris muriatici. S. ae'theris ...
  6. NLM Digital Collections - Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia : effectiveness and value ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 22, 2017
    ... at least 3 months. : Incidence of AEs, serious AEs, Study dose is reached • History of being compliant with severe ... disorder with stable Male, % 2) -3.5 ≥1 AE, % (Initial dose of 40 mg/day regimens of concomitant 14. ...
  7. ... gen- liana, summit, chamadr., centaur, min. aa p. ae.) Dose, 3 ss to 3j. Pulvis e Gummi Gutta, P. ... tana- ceti, fol. scordii, senna, rhmi. aa. p. ae, fiat pulvis. Ph. P.) Dose, 9 j to 3 j. Pulvis Ipecacuanha Compositus, ...
  8. ... aristoloch., gentianx, summit, chamozdr., centaur, ruin, aa p.ae.) Dose, gss to gj. Pulvis Emmenagogus, P. myrrhae compo- ... absinth., tanaceti, fol. scordii, sennx, rhei. aa p. ae, fiat pulvis. Ph. P.) Dose, ^j to gj. Pulvis Hydragogcs, P. e gummi ...
  9. ... aristoloch., gentiana, summit, chamadr., centaur, min. aa p. ae.) Dose, Pulvis Emmenagogus, P. myrrhae compositus - p. Epilepticus Marchionum, ... absinth., tanaceti, fol. scordii, senna, rhei. aa p. ae, fiat pulvis. Ph. P.) Dose, to 3j. . Pulvis Hydragogus, P. e gummi guttfi- ...
  10. ... early: 2.5% (2/79) Discontinuation due to AEs during open-label dose titration phase: 12% (12/103) Discontinuation due to AEs during double-blind phase: 2.5% (2/79) ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last